7 active not recruiting, 6 completed, 5 terminated, 4 recruiting. 15 Phase 1, 14 Phase 2.
Follow Platinum-Resistant Fallopian Tube Carcinoma: new trials by email Literature Review of Platinum-Resistant Fallopian Tube Carcinoma trials Research Report on Platinum-Resistant Fallopian Tube Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Lorigerlimab in Participants With Advanced Solid Tumors Lorigerlimab - Platinum-resistant Ovarian Cancer, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | MacroGenics | 80 | 2025-05-01 | 2026-06-02 |
| Niraparib and Selenium for the Treatment of Recurrent BRCA Negative Platinum Resistant Ovarian Cancer Biopsy, Biospecimen Collection, Niraparib - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Withdrawn | City of Hope Medical Center | 2025-04-18 | 2025-05-23 | |
| MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer Autologous MUC1-activated T-cells, Bendamustine, Biospecimen Collection - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Recruiting | Mayo Clinic | 12 | 2024-09-20 | 2026-03-16 |
| Vismodegib Combined With Atezolizumab in Platinum Resistant Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Vismodegib, Atezolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma | Phase 2 | Recruiting | Ronald Buckanovich | 48 | 2023-05-15 | 2026-06-18 |
| PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Biopsy, Pegylated SN-38 Conjugate PLX038, Computed Tomography - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Mayo Clinic | 20 | 2022-09-14 | 2026-07-16 |
| Phase 1b Study of SL-172154 Administered With Combination Agent(s) in Subjects With Ovarian Cancers Pegylated Liposomal Doxorubicin + SL-172154, Mirvetuximab + SL-172154 - Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer | Phase 1 | Completed | Shattuck Labs, Inc. | 86 | 2022-08-18 | 2025-12-23 |
| Oncolytic Adenovirus Coding for TNFa and IL2 (TILT-123) With Pembrolizumab or Pembrolizumab (Phase 1a) and Pegylated Liposomal Doxorubicin (Phase 1b) as Treatment for Ovarian Cancer. TILT-123, pembrolizumab, pegylated liposomal doxorubicin - Platinum-refractory Ovarian Carcinoma, Platinum-resistant Ovarian Cancer | Phase 1 / Phase 2 | Active not recruiting | TILT Biotherapeutics Ltd. | 29 | 2022-05-17 | 2026-05-05 |
| Lenvatinib, Pembrolizumab, and Paclitaxel for Treatment of Recurrent Endometrial, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Lenvatinib, Paclitaxel, Pembrolizumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Active not recruiting | Floor Backes, MD | 38 | 2021-09-01 | 2026-10-21 |
| Testing the Addition of an Anti-cancer Drug, Elimusertib (BAY 1895344) ATR Inhibitor, to the Chemotherapy Treatment (Gemcitabine) for Advanced Pancreatic and Ovarian Cancer, and Advanced Solid Tumors Biopsy Procedure, Biospecimen Collection, Diagnostic Imaging Testing - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 | Active not recruiting | National Cancer Institute (NCI) | 14 | 2021-06-01 | 2026-07-31 |
| Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Irinotecan Sucrosofate - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 2 | Completed | Northwestern University | 3 | 2021-03-16 | 2023-01-19 |
| Chk2 Inhibitor for Recurrent EpitheliAl periToneal, fallopIan or oVarian cancEr (CREATIVE Phase IA Trial) PHI-101 administration - Platinum-resistant Ovarian Cancer, Platinum-refractory Ovarian Carcinoma | Phase 1 | Unknown | Seoul National University Hospital | 36 | 2020-12-17 | 2023-06-26 |
| A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies ATRC-101, Pembrolizumab, Pegylated liposomal doxorubicin (PLD) - Breast Cancer, Colorectal Cancer | Phase 1 | Terminated | Atreca, Inc. | 87 | 2020-02-11 | 2023-12-29 |
| ONC201 Plus Weekly Paclitaxel in Patients With Platinum Refractory or Resistant Ovarian Cancer Akt/ERK Inhibitor ONC201, Paclitaxel, Questionnaire Administration - Malignant Ovarian Epithelial Tumor, Platinum-Resistant Fallopian Tube Carcinoma | Phase 2 | Recruiting | Ira Winer | 62 | 2020-01-21 | 2026-06-17 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
| Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer PRGN-3005 UltraCAR-T cells - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Active not recruiting | Precigen, Inc | 71 | 2019-04-30 | 2024-11-08 |
| Genetically Engineered Cells (NY-ESO-1 TCR Engineered T Cells and HSCs) After Melphalan Conditioning Regimen in Treating Patients With Recurrent or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Aldesleukin, Autologous NY-ESO-1-specific CD8-positive T Lymphocytes, Cellular Therapy - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 | Terminated | Roswell Park Cancer Institute | 4 | 2019-03-08 | 2024-09-19 |
| Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Anetumab Ravtansine, Bevacizumab, Paclitaxel - Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube High Grade Serous Adenocarcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 96 | 2018-10-12 | 2026-10-13 |
| Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis Ipilimumab, Laboratory Biomarker Analysis, Nivolumab - Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm | Phase 1 | Completed | M.D. Anderson Cancer Center | 26 | 2018-09-21 | 2025-05-22 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
| Gene-Modified T Cells With or Without Decitabine in Treating Patients With Advanced Malignancies Expressing NY-ESO-1 Cyclophosphamide, Decitabine, Laboratory Biomarker Analysis - Advanced Fallopian Tube Carcinoma, Advanced Malignant Solid Neoplasm | Phase 1 / Phase 2 | Active not recruiting | Roswell Park Cancer Institute | 15 | 2017-07-14 | 2026-07-08 |
Showing 20 of 24. Sign in to see all of them.
Ovarian Neoplasms (17) · Fallopian Tube Neoplasms (16) · Endometrial Neoplasms (3) · Breast Neoplasms (2) · Melanoma (2) · Triple Negative Breast Neoplasms (2) · Adenoviridae Infections (1) · Carcinoma, Hepatocellular (1) · Carcinoma, Non-Small-Cell Lung (1) · Carcinoma, Ovarian Epithelial (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Esophageal Squamous Cell Carcinoma (1) · Neoplasm Metastasis (1) · Pancreatic Neoplasms (1)
Neoplasms (19) · Neoplasms by Site (19) · Female Urogenital Diseases (18) · Female Urogenital Diseases and Pregnancy Complications (18) · Genital Diseases (18) · Genital Diseases, Female (18) · Genital Neoplasms, Female (18) · Urogenital Diseases (18) · Urogenital Neoplasms (18) · Adnexal Diseases (17) · Endocrine Gland Neoplasms (17) · Endocrine System Diseases (17) · Gonadal Disorders (17) · Ovarian Diseases (17) · Fallopian Tube Diseases (16)
Disulfides (6) · Immunoglobulin G (6) · Taxes (5) · Bevacizumab (4) · Paclitaxel (4) · Specimen Handling (4) · liposomal doxorubicin (4) · 1-dodecylpyridoxal (3) · Biopsy (3) · pembrolizumab (3) · Cyclophosphamide (2) · Gemcitabine (2) · Leukapheresis (2) · atezolizumab (2) · durvalumab (2)
Mayo Clinic (4) · National Cancer Institute (NCI) (4) · M.D. Anderson Cancer Center (3) · Roswell Park Cancer Institute (2) · Atreca, Inc. (1) · City of Hope Medical Center (1) · Floor Backes, MD (1) · Ira Winer (1) · MacroGenics (1) · Northwestern University (1) · Precigen, Inc (1) · Ronald Buckanovich (1) · Seoul National University Hospital (1) · Shattuck Labs, Inc. (1) · TILT Biotherapeutics Ltd. (1)
United States (22) · Canada (3) · South Korea (2) · Finland (1) · Spain (1) · United Kingdom (1)
Amir A Jazaeri (3) · Amy R. Lankford, PhD (1) · Andrea E. Wahner Hendrickson, M.D. (1) · Brenda J. Ernst, M.D. (1) · Daniela E Matei, M.D. (1) · Emese Zsiros, MD (1) · Evanthia Galanis, M.D. (1) · Floor Backes, MD (1) · Hee Seung Kim, MD (1) · Ira Winer, M.D. (1) · James M Cleary (1) · Kunle Odunsi (1) · Lorna Rodriguez-Rodriguez (1) · Matthew S. Block, M.D., Ph.D. (1) · Panagiotis A Konstantinopoulos (1)
PMID 34980026, PMID 38009662, PMID 38471508, PMID 39506856, PMID 41566775, PMID 41951722
P30CA016056 (2), UM1CA186709 (2), P30CA033572 (1), P30CA060553 (1), P50CA136393 (1), R01CA164333 (1), UM1CA186644 (1)